Using aspirin to prevent cognitive decline

BMJ 2008; 337 doi: 10.1136/bmj.a958 (Published 1 September 2008)
Cite this as: BMJ 2008;337:a958

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. John W Eikelboom, associate professor,
  2. Martin O’Donnell, associate professor
  1. 1McMaster University, Hamilton, Canada L8S 4L8
  1. eikelbj{at}mcmaster.ca

    Is not effective in asymptomatic middle aged to elderly adults

    The rationale for using aspirin to prevent mild cognitive impairment and dementia seems compelling. Disorders of cognition affect 10-15% of the general population over 65.1 2 Cerebrovascular disease plays a pivotal role in the development and progression of mild cognitive impairment and dementia.1 2 Aspirin prevents first ever stroke in apparently healthy asymptomatic women,3 and it also prevents first ever and recurrent stroke in high risk populations.4 Thus, by preventing cerebral ischaemia, aspirin would be expected to reduce the burden of cognitive loss to individuals and society. Observational studies have shown an association between the use of aspirin and reduced odds of cognitive impairment,5 6 but randomised controlled trials have been lacking until recently.

    In the linked study (doi: 10.1136/bmj.a1198), Price and colleagues report cognitive outcomes from the aspirin for asymptomatic atherosclerosis (AAA) trial, which randomised 3350 middle aged …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL